ALIGOS THERAPEUTICS INC (ALGS) Stock Fundamental Analysis

NASDAQ:ALGS • US01626L2043

7.09 USD
+0.15 (+2.16%)
At close: Feb 24, 2026
6.51 USD
-0.58 (-8.18%)
After Hours: 2/24/2026, 8:08:24 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, ALGS scores 2 out of 10 in our fundamental rating. ALGS was compared to 521 industry peers in the Biotechnology industry. ALGS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ALGS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ALGS had negative earnings in the past year.
  • In the past year ALGS has reported a negative cash flow from operations.
  • In the past 5 years ALGS always reported negative net income.
  • In the past 5 years ALGS always reported negative operating cash flow.
ALGS Yearly Net Income VS EBIT VS OCF VS FCFALGS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • ALGS has a worse Return On Assets (-78.77%) than 66.22% of its industry peers.
  • ALGS's Return On Equity of -120.37% is in line compared to the rest of the industry. ALGS outperforms 40.50% of its industry peers.
Industry RankSector Rank
ROA -78.77%
ROE -120.37%
ROIC N/A
ROA(3y)-103.51%
ROA(5y)-81.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALGS Yearly ROA, ROE, ROICALGS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • ALGS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALGS Yearly Profit, Operating, Gross MarginsALGS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ALGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ALGS has been reduced compared to 1 year ago.
  • ALGS has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ALGS is higher compared to a year ago.
ALGS Yearly Shares OutstandingALGS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ALGS Yearly Total Debt VS Total AssetsALGS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • ALGS has an Altman-Z score of -8.83. This is a bad value and indicates that ALGS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of ALGS (-8.83) is worse than 69.67% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that ALGS is not too dependend on debt financing.
  • ALGS's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. ALGS outperforms 50.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.83
ROIC/WACCN/A
WACC8.65%
ALGS Yearly LT Debt VS Equity VS FCFALGS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • ALGS has a Current Ratio of 4.70. This indicates that ALGS is financially healthy and has no problem in meeting its short term obligations.
  • ALGS has a Current ratio (4.70) which is in line with its industry peers.
  • A Quick Ratio of 4.70 indicates that ALGS has no problem at all paying its short term obligations.
  • With a Quick ratio value of 4.70, ALGS perfoms like the industry average, outperforming 55.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.7
Quick Ratio 4.7
ALGS Yearly Current Assets VS Current LiabilitesALGS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 24.04% over the past year.
  • ALGS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -55.88%.
  • ALGS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.28% yearly.
EPS 1Y (TTM)24.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.98%
Revenue 1Y (TTM)-55.88%
Revenue growth 3Y-3.28%
Revenue growth 5YN/A
Sales Q2Q%-41.61%

3.2 Future

  • Based on estimates for the next years, ALGS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.34% on average per year.
  • ALGS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 119.76% yearly.
EPS Next Y23.93%
EPS Next 2Y16.58%
EPS Next 3Y13%
EPS Next 5Y20.34%
Revenue Next Year-31.96%
Revenue Next 2Y-24.66%
Revenue Next 3Y-24.16%
Revenue Next 5Y119.76%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALGS Yearly Revenue VS EstimatesALGS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ALGS Yearly EPS VS EstimatesALGS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALGS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALGS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALGS Price Earnings VS Forward Price EarningsALGS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALGS Per share dataALGS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALGS's earnings are expected to grow with 13.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.58%
EPS Next 3Y13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ALGS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALIGOS THERAPEUTICS INC

NASDAQ:ALGS (2/24/2026, 8:08:24 PM)

After market: 6.51 -0.58 (-8.18%)

7.09

+0.15 (+2.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-09
Inst Owners49.58%
Inst Owner Change-4.58%
Ins Owners2.13%
Ins Owner Change0%
Market Cap43.60M
Revenue(TTM)2.65M
Net Income(TTM)-86.46M
Analysts83.64
Price Target69.56 (881.1%)
Short Float %6.12%
Short Ratio4.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.17%
Min EPS beat(2)-56.86%
Max EPS beat(2)36.53%
EPS beat(4)2
Avg EPS beat(4)-6.95%
Min EPS beat(4)-56.86%
Max EPS beat(4)36.53%
EPS beat(8)4
Avg EPS beat(8)7.35%
EPS beat(12)6
Avg EPS beat(12)6.33%
EPS beat(16)8
Avg EPS beat(16)7.12%
Revenue beat(2)2
Avg Revenue beat(2)81.81%
Min Revenue beat(2)45.29%
Max Revenue beat(2)118.33%
Revenue beat(4)3
Avg Revenue beat(4)49.35%
Min Revenue beat(4)-8.53%
Max Revenue beat(4)118.33%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-15.02%
EPS NQ rev (1m)-17.4%
EPS NQ rev (3m)7.63%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)20%
Revenue NY rev (1m)-4.94%
Revenue NY rev (3m)-3.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.48
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 0.61
EV/EBITDA N/A
EPS(TTM)-10.08
EYN/A
EPS(NY)-7.16
Fwd EYN/A
FCF(TTM)-12.93
FCFYN/A
OCF(TTM)-12.87
OCFYN/A
SpS0.43
BVpS11.68
TBVpS11.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -78.77%
ROE -120.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.51%
ROA(5y)-81.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.81%
Cap/Sales 14.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.7
Quick Ratio 4.7
Altman-Z -8.83
F-Score4
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)18.19%
Cap/Depr(5y)31.84%
Cap/Sales(3y)3.39%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.98%
EPS Next Y23.93%
EPS Next 2Y16.58%
EPS Next 3Y13%
EPS Next 5Y20.34%
Revenue 1Y (TTM)-55.88%
Revenue growth 3Y-3.28%
Revenue growth 5YN/A
Sales Q2Q%-41.61%
Revenue Next Year-31.96%
Revenue Next 2Y-24.66%
Revenue Next 3Y-24.16%
Revenue Next 5Y119.76%
EBIT growth 1Y12.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.43%
EBIT Next 3Y-8.8%
EBIT Next 5Y-12.52%
FCF growth 1Y-8.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.26%
OCF growth 3YN/A
OCF growth 5YN/A

ALIGOS THERAPEUTICS INC / ALGS FAQ

Can you provide the ChartMill fundamental rating for ALIGOS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to ALGS.


What is the valuation status of ALIGOS THERAPEUTICS INC (ALGS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALIGOS THERAPEUTICS INC (ALGS). This can be considered as Overvalued.


How profitable is ALIGOS THERAPEUTICS INC (ALGS) stock?

ALIGOS THERAPEUTICS INC (ALGS) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for ALGS stock?

The Earnings per Share (EPS) of ALIGOS THERAPEUTICS INC (ALGS) is expected to grow by 23.93% in the next year.